Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.
Adenocarcinoma
/ mortality
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Combined Modality Therapy
Female
Fluorouracil
/ therapeutic use
Follow-Up Studies
Humans
Irinotecan
/ therapeutic use
Leucovorin
/ therapeutic use
Male
Middle Aged
Nomograms
Oxaliplatin
/ therapeutic use
Pancreatectomy
/ mortality
Pancreatic Neoplasms
/ mortality
Prognosis
Prospective Studies
Survival Rate
FOLFIRINOX
chemotherapy
locally advanced pancreatic cancer
resection
survival
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
07
04
2021
received:
19
11
2020
accepted:
15
05
2021
pubmed:
12
6
2021
medline:
20
8
2021
entrez:
11
6
2021
Statut:
ppublish
Résumé
Patients with locally advanced pancreatic cancer (LAPC) are increasingly treated with FOLFIRINOX, resulting in improved survival and resection of tumors that were initially unresectable. It remains unclear, however, which specific patients benefit from FOLFIRINOX. Two nomograms were developed predicting overall survival (OS) and resection at the start of FOLFIRINOX for LAPC. From our multicenter, prospective LAPC registry in 14 Dutch hospitals, LAPC patients starting first-line FOLFIRINOX (April 2015-December 2017) were included. Stepwise backward selection according to the Akaike Information Criterion was used to identify independent baseline predictors for OS and resection. Two prognostic nomograms were generated. A total of 252 patients were included, with a median OS of 14 months. Thirty-two patients (13%) underwent resection, with a median OS of 23 months. Older age, female sex, Charlson Comorbidity Index ≤1, and CA 19.9 < 274 were independent factors predicting a better OS (c-index: 0.61). WHO ps >1, involvement of the superior mesenteric artery, celiac trunk, and superior mesenteric vein ≥ 270° were independent factors decreasing the probability of resection (c-index: 0.79). Two nomograms were developed to predict OS and resection in patients with LAPC before starting treatment with FOLFIRINOX. These nomograms could be beneficial in the shared decision-making process and counseling of these patients.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Patients with locally advanced pancreatic cancer (LAPC) are increasingly treated with FOLFIRINOX, resulting in improved survival and resection of tumors that were initially unresectable. It remains unclear, however, which specific patients benefit from FOLFIRINOX. Two nomograms were developed predicting overall survival (OS) and resection at the start of FOLFIRINOX for LAPC.
METHODS
METHODS
From our multicenter, prospective LAPC registry in 14 Dutch hospitals, LAPC patients starting first-line FOLFIRINOX (April 2015-December 2017) were included. Stepwise backward selection according to the Akaike Information Criterion was used to identify independent baseline predictors for OS and resection. Two prognostic nomograms were generated.
RESULTS
RESULTS
A total of 252 patients were included, with a median OS of 14 months. Thirty-two patients (13%) underwent resection, with a median OS of 23 months. Older age, female sex, Charlson Comorbidity Index ≤1, and CA 19.9 < 274 were independent factors predicting a better OS (c-index: 0.61). WHO ps >1, involvement of the superior mesenteric artery, celiac trunk, and superior mesenteric vein ≥ 270° were independent factors decreasing the probability of resection (c-index: 0.79).
CONCLUSIONS
CONCLUSIONS
Two nomograms were developed to predict OS and resection in patients with LAPC before starting treatment with FOLFIRINOX. These nomograms could be beneficial in the shared decision-making process and counseling of these patients.
Substances chimiques
folfirinox
0
Oxaliplatin
04ZR38536J
Irinotecan
7673326042
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
589-597Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Reames BN , Blair AB , Krell RW , et al. Management of locally advanced pancreatic cancer: results of an international survey of current practice. Ann Surg. 2019;273:1173-1181.
Philip PA . Locally advanced pancreatic cancer: where should we go from here? J Clin Oncol. 2011;29(31):4066-4068.
Tempero MA , Malafa MP , Al-Hawary M , et al. Pancreatic adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(8):1028-1061.
Abendroth A , Noureddine R , Abramczyk M , et al. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. J Cancer Res Clin Oncol. 2019;145(2):445-455.
Suker M , Beumer BR , Sadot E , et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801-810.
Rombouts SJ , Walma MS , Vogel JA , et al. Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. Ann Surg Oncol. 2016;23(13):4352-4360.
Sadot E , Doussot A , O'reilly EM , et al. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22(11):3512-3521.
Maggino L , Malleo G , Marchegiani G , et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154(10):932-942.
Conroy T , Desseigne F , Ychou M , et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825.
Rombouts SJ , Mungroop TH , Heilmann MN , et al. FOLFIRINOX in locally advanced and metastatic pancreatic cancer: a single centre cohort study. J Cancer. 2016;7(13):1861-1866.
Hackert T , Sachsenmaier M , Hinz U , et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg. 2016;264(3):457-463.
Gemenetzis G , Groot VP , Blair AB , et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270(2):340-347.
Marthey L , Sa-Cunha A , Blanc JF , et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22(1):295-301.
Balachandran VP , Gonen M , Smith JJ , DeMatteo RP . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173-e180.
Strijker M , Mackay TM , Bonsing BA , et al. Establishing and Coordinating a Nationwide Multidisciplinary Study Group: lessons Learned by the Dutch Pancreatic Cancer Group. Ann Surg. 2020;271(4):e102-e104.
Versteijne E , van Eijck CH , Punt CJ , et al. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials. 2016;17(1):127.
Amin M , Edge S , Greene F , Byrd D , Brookland R , Washington M . AJCC Cancer Staging Manual. 8th ed. Berlin: Springer; 2017.
Eisenhauer EA , Therasse P , Bogaerts J , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
Moons KGM , Wolff RF , Riley RD , et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med. 2019;170(1):W1-W33.
Collins GS , Reitsma JB , Altman DG , Moons KGM . Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594.
Choi SH , Park SW , Seong J . A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiother Oncol. 2018;129(2):340-346.
Vernerey D , Huguet F , Vienot A , et al. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). Br J Cancer. 2016;115(3):281-289.
Higuera O , Ghanem I , Nasimi R , Prieto I , Koren L , Feliu J . Management of pancreatic cancer in the elderly. World J Gastroenterol. 2016;22(2):764-775.
Castel-Kremer E , De Talhouet S , Charlois A-L , et al. An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma. J Geriatr Oncol. 2018;9(4):373-381.
Chen H-L , Zhou M-Q , Tian W , Meng K-X , He H-F . Effect of age on breast cancer patient prognoses: a population-based study using the SEER 18 database. PLOS One. 2016;11(10):e0165409.
van Eeghen EE , Bakker SD , van Bochove A , Loffeld RJLF . Impact of age and comorbidity on survival in colorectal cancer. J Gastrointest Oncol. 2015;6(6):605-612. https://doi.org/10.3978/j.issn.2078-6891.2015.070
Vainshtein JM , Schipper M , Zalupski MM , et al. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escala. Int J Radiat Oncol Biol Phys. 2013;86(1):96-101.
Peixoto RD , Speers C , McGahan CE , Renouf DJ , Schaeffer DF , Kennecke HF . Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med. 2015;4(8):1171-1177.
Hohla F , Hopfinger G , Romeder F , et al. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. Int J Oncol. 2014;44(1):319-326.
Cai S , Hong TS , Goldberg SI , et al. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer. 2013;119(23):4196-4204.
Dohopolski MJ , Glaser SM , Vargo JA , Balasubramani GK , Beriwal S . Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancer-patterns of care and overall survival. J Gastrointest Oncol. 2017;8(5):766-777.
Park HM , Park S-J , Han S-S , Kim SH . Surgery for elderly patients with resectable pancreatic cancer, a comparison with non-surgical treatments: a retrospective study outcomes of resectable pancreatic cancer. BMC Cancer. 2019;19(1):1090.
Nakai Y , Isayama H , Sasaki T , et al. Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Crit Rev Oncol Hematol. 2011;78(3):252-259.
Isaji S , Mizuno S , Windsor JA , et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2-11.
van Veldhuisen E , Vogel JA , Klompmaker S , et al. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. HPB. 2018;20(7):605-611.
Aoki S , Motoi F , Murakami Y , et al. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. BMC Cancer. 2019;19(1):252.
Seufferlein T , Hammel P , Delpero JR , et al. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: expert opinion based on a review of current evidence. Cancer Treat Rev. 2019;77:1-10.
Katz MH , Fleming JB , Bhosale P , et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749-5756.
Verbeke C , Lohr M , Karlsson JS , Del , Chiaro M . Pathology reporting of pancreatic cancer following neoadjuvant therapy: challenges and uncertainties. Cancer Treat Rev. 2015;41(1):17-26.
Bednar F , Zenati MS , Steve J , et al. Analysis of predictors of resection and survival in locally advanced stage III pancreatic cancer: does the nature of chemotherapy regimen influence outcomes? Ann Surg Oncol. 2017;24(5):1406-1413.
Klompmaker S , Peters NA , van Hilst J , et al. Outcomes and risk score for distal pancreatectomy with celiac axis resection (DP-CAR): an International Multicenter Analysis. Ann Surg Oncol. 2019;26(3):772-781.
Hosokawa Y , Nagakawa Y , Sahara Y , et al. Surgical outcomes of pancreaticoduodenectomy for pancreatic cancer with proximal dorsal jejunal vein involvement. J Gastrointest Surg. 2018;22(7):1179-1185.
Springfeld C , Jäger D , Büchler MW , et al. Chemotherapy for pancreatic cancer. Presse Med. 2019;48(3 Pt 2):e159-e174.
Reni M , Zanon S , Balzano G , et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(11):2786-2792.